Fortive Corporation

▲ Bull Case

• ◆Software ARR within IOS accelerates to 12-15%/yr; multiple re-rates to 28x+. ServiceChannel, Accruent, and Gordian are genuine software businesses that should trade at 25-30x+ free cash flow when recognized as software. If IOS software ARR becomes publicly disclosed and shows 12-15% growth, FTV transitions from 'industrial' to 'industrial software' in market perception — a multiple expansion from 20x to 28-32x. At 28x × FY2027E EPS $3.80: $106/share.
• ◆AHS rebounds AND IOS maintains 5%+ core growth simultaneously — double organic growth driver. If healthcare capital budgets normalize in 2026-2027 AND IOS software + safety continue at 5%+, total portfolio organic growth reaches 5-6% for the first time since the early-2020s, warranting a full Danaher-adjacent re-rating.
• ◆FTV as M&A target. At ~$18.4B market cap, Fortive is within acquisition range for several strategic buyers (Honeywell, Emerson, Parker Hannifin, or a PE firm). FBS + IOS software platform + AHS sterilization defensibility makes it an attractive strategic asset. A takeout at 28-30x EPS = $93-100/share.

▼ Bear Case

• ◆'Fortive Accelerated' fails to accelerate organic growth; Q1 2026 was one-time. FY2025's +1.7% core growth was weak for an FBS compounder; if Q1 2026's +5.3% was driven by project timing (Gordian contract lumping, STERRAD procurement timing) rather than structural acceleration, FY2026 reverts to +2-3% core. With a new CEO + new CFO simultaneously, execution uncertainty is real. P/E compresses to 17x → $48/share.
• ◆AHS healthcare headwinds persist longer than expected. Hospital systems remain under cost pressure from Medicaid reimbursement cuts and labor inflation; capital equipment purchases (including sterilization) remain deferred for a third consecutive year. AHS core growth -1% to -2% while IOS runs at only +3%; blended portfolio core growth 1-2% → no valuation re-rating.
• ◆New CEO + new CFO = simultaneous leadership transition disrupts FBS culture. Both CEO and CFO are new within 12 months of each other. FBS is a culture-dependent system; if new leadership changes strategy emphasis, acquisition pace, or capital allocation, the operational excellence engine slows. This is the most idiosyncratic risk — not market-driven, but execution-driven.

“Is Q1 2026's +5.3% core growth the start of a structural acceleration (Fortive Accelerated thesis), or is it a one-quarter timing artifact that will revert to 1-3% core in subsequent quarters? The bull says: The Ralliant spin removed the primary drag on organic growth; IOS software businesses are growing; 'Fortive Accelerated' under Soroye has structural initiatives (customer success, cross-sell, focused M&A) that take 2-3 quarters to build momentum; Q1 is the first quarter where the new portfolio + new strategy are fully in place. The bear says: Q1 2026 core growth included project timing and year-over-year comparisons that were easy (Q1 2025 was weak); FY2025's +1.7% full-year core growth is the real baseline; the AHS healthcare drag is structural; FBS can expand margins but cannot manufacture organic growth without market tailwinds. Key monitor: FY2026 full-year core growth. If FY2026 finishes at ≥4% core, bull thesis is on track. If FY2026 finishes at 2-3% core, the acceleration thesis is unconfirmed.”

• ◆Q2 2026 earnings (July): Second consecutive quarter of 4%+ core growth — most important near-term bull vs. bear resolution catalyst
• ◆Q3–Q4 2026 earnings: Third and fourth consecutive quarters of 4%+ core growth confirming Fortive Accelerated structural acceleration
• ◆FY2026 full-year result: First full post-Ralliant year; core growth ≥4% and adj. EPS $2.97+ confirms re-rating thesis
• ◆IOS software ARR disclosure: Any management commentary or filing disclosing software ARR/NRR would trigger multiple re-rating from industrial to industrial-software valuation
• ◆AHS healthcare recovery signals: Hospital capex improvement and ASP/STERRAD order recovery would resolve the AHS bear case
• ◆CEO Soroye 12-month strategy update (June 2026): Formal strategic plan with organic growth targets, software ARR goals, and M&A criteria would be a major information event
• ◆M&A announcement post-deleveraging: FTV returns to acquisitions when net debt approaches $1B (FY2027); deal quality vs. FBS IRR thesis is key

• ◆Organic growth reverts to 1-3% (Fortive Accelerated fails) — HIGH severity, 25% probability; monitor Q2–Q3 2026 core growth vs. 4%+ target
• ◆AHS healthcare headwinds persist more than 2 years — MEDIUM severity, 25% probability; monitor hospital capital budget reports and ASP/STERRAD order commentary
• ◆New CEO/CFO leadership transition disrupts FBS culture — MEDIUM severity, 15% probability; monitor employee turnover and FBS initiative commentary
• ◆Large M&A at unattractive prices (>20x EBITDA) during deleveraging window — MEDIUM severity, 15% probability; monitor any M&A announcement and deal multiples
• ◆Software ARR growth disappointment — MEDIUM severity, 30% probability; monitor IOS core growth breakdown and any ARR disclosure
• ◆Macro recession causing industrial capex freeze — HIGH severity, 5-10% probability; monitor PMI, industrial capex surveys, and customer commentary
• ◆Competition in facilities management SaaS eroding ServiceChannel market share — LOW-MEDIUM severity, 20% probability; monitor competitive pricing and market share trends